Fidelity Biosciences News - Fidelity Biosciences invests venture capital in private biopharmaceutical and medical technology companies.

News Highlights:

December 14, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts... View Full Article

Governor Patrick Highlights Progress on the Massachusetts-China Relationship

December 10, 2007 - Governor Deval Patrick today highlighted progress made on the Massachusetts-China relationship during the Commonwealth’s first governor-led trade mission to China in seven years, including agreements signed between life science and clean energy groups... View Full Article

$22 Million to Help Acorn Fund Heart Device

December 9, 2007 - A small New Brighton company that has developed a unique device to treat patients who have heart failure said Wednesday that it has secured $22 million in financing. View Full Article

Topaz Pharmaceuticals Receives $20 Million Series A Financing

December 3, 2007 - (HSMN NewsFeed)--Topaz Pharmaceuticals Inc., a pharmaceutical company dedicated to the health and well being of children, today announced that it has secured $20 million in Series A financing from Aisling Capital (New York) and Fidelity Biosciences (Boston). View Full Article

WuXi PharmaTech (NYSE:WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award

October 29, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Dr. Ge Li, the company's Chairman and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year (EOY) China 2007 Award. View Full Article

WuXi PharmaTech (NYSE:WX) Ranked the 28th of Deloitte Technology Fast 50 China

October 26, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been ranked the 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. View Full Article

Favorable Pharmacokinetic & Safety Data Observed in First Clinical Trial of Novel Fleximer Anticancer Agent

October 24, 2007 - Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and... View Full Article

Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's Schizophrenia and Huntington's Diseases

October 17, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimer’s, Schizophrenia and Huntington’s diseases. View Full Article

EnVivo Announces Hiring of Chief Medical Officer

September 25, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced the appointment of Dr.Dana C. Hilt as Senior Vice President and Chief Medical Officer. View Full Article

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

September 17, 2007 - Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX), today announced that they have entered into a 50/50 partnership in the United States to co-develop and co-market Microbia’s first-in-class compound linaclotide. Linaclotide is currently being investigated... View Full Article

WuXi PharmaTech (NYSE:WX) Announces Closing of Initial Public Offering

August 14, 2007 - WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company in the growing global drug R&D outsourcing market, announced today the closing of its... View Full Article

FoldRX and Cystic Fibrosis Foundation Therapeutics Announce $22 Million Collaboration

August 13, 2007 - FoldRx Pharmaceuticals, Inc. (FoldRx) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today that FoldRx will receive up to $22 million over five years to discover and develop... View Full Article

Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors

July 12, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today the appointment of Nicholas G. Bacopoulos, Ph.D. to its Board of Directors. A 24-year industry veteran, Dr. Bacopoulos brings to Mersana extensive top-level management experience in the... View Full Article

BIOGEN IDEC AND CARDIOKINE PARTNER TO DEVELOP LIXIVAPTAN, A NOVEL VASOPRESSIN ANTAGONIST

July 2, 2007 - Biogen Idec (NASDAQ: BIIB) and Cardiokine, Inc., a privately-held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, today announced the signing of an agreement to jointly develop lixivaptan, an... View Full Article

U.S. Genomics Recognized for Outstanding Entrepreneurship by the National Science Foundation (NSF)

June 12, 2007 - U.S. Genomics Inc, a pioneer of single molecule biology technologies for the biodefense and life sciences industries, has been recognized by the NSF for outstanding entrepreneurship at its May NSF SBIR /STTR (Small Business Innovation Research/Small Business... View Full Article

Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors

May 30, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today that it has initiated a Phase I open-label, dose-escalation trial of its lead product candidate, XMT-1001, in patients with solid tumors. XMT-1001 is a polymer-based prodrug of... View Full Article

Microbia Announces Positive Phase 2 Results for its Investigational Compound Linaclotide

May 21, 2007 - Microbia today announced the presentation of data from a Phase 2 study in which linaclotide accelerated colonic transit and improved bowel function in patients with constipation-predominant irritable bowel syndrome (IBS-C). These data also showed... View Full Article

U. S. Genomics Awarded $8.6 Million for Phase III Bio-Defense Contract

May 15, 2007 - U.S. Genomics has been awarded an $8.6 million Phase III contract by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate to continue development of the Company's sophisticated biological sensor for biodefense applications. Under the... View Full Article

Mersana Therapeutics, Inc. Announces the Appointment of Robert J. Fram, M.D. as Chief Medical Officer

May 11, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today the appointment of Robert J. Fram, M.D., F.A.C.P. in the newly created position of Chief Medical Officer. Dr. Fram will oversee all clinical and medical activities at the company as it moves forward with... View Full Article

U.S. Genomics Appoints Salamone to Its Board of Directors

May 8, 2007 - U.S. Genomics announced today that Salvatore J. Salamone, Ph.D., has joined the company's Board of Directors. Dr. Salamone is presently also Chairman and Chief Executive Officer of Saladax BioMedical Inc., a developer of chemotherapy monitoring... View Full Article

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting

April 13, 2007 - Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place... View Full Article

Bioconnect Systems Completes $8M Series A Financing

April 5, 2007 - (BUSINESS WIRE)--Bioconnect Systems, Inc. announced today that the company has raised $8 million in Series A financing. Bioconnect’s initial product platform, the Optiflow™, enables surgeons to create precisely controlled connections throughout the body. View Full Article

Intranasal Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran

April 4, 2007 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced the appointment of Peter F. Young as President and Chief Executive Officer. Mr. Young was most recently the President and CEO of AlphaVax, a privately held biotechnology company based in Research Triangle Park, NC. He will be based in ITI’s corporate headquarters in Montvale, NJ. View Full Article

U.S. Genomics & The Biophysical Society Honor Howard C. Berg with Outstanding Investigator

March 5, 2007 - U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society's annual award for... View Full Article

U.S. Genomics & The Biophysical Society Honor Howard C. Berg with Outstanding Investigator

March 3, 2007 - U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society's annual award for... View Full Article

Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology

January 19, 2007 - In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation, Quest Diagnostics Incorporated (NYSE: DGX) today announced the signing of a worldwide license... View Full Article